Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia

References

• Pallis AG. A review of treatment in non-small-cell lung cancer. Eur Oncol Haematol. 2012;8:208–212.
   Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594.
   PubMed Web of Science ®Google Scholar
• Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo. Situación del cáncer en la población adulta atendida en el SGSSS de Colombia. Bogotá (DC): Fondo colombiano de enfermedades de alto costo; 2017.
   Google Scholar
• Herbst R, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–454.
   PubMed Web of Science ®Google Scholar
• Liao B-C, Lin -C-C, Yang JC-H. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27:94–101.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). Sistema de Trámites en Linea - Consultas Públicas [ Internet]. 2019 [cited 2019 Mar 19].  Available from: http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp
   Google Scholar
• Instituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas. Bogotá (DC): IETS; 2014.
   Google Scholar
• Park K, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–589.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:270–277.
   PubMed Web of Science ®Google Scholar
• Urata Y, Katakami N, Morita S, et al. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016;34:3248–3257.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Zhou Q, Yan HH, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017;116:568–574.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–125.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.
   PubMed Web of Science ®Google Scholar
• Holleman MS, van Tinteren H, Groen HJM, et al. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther. 2019;12:1413–1421.
   PubMed Web of Science ®Google Scholar
• Hochmair MJ, Morabito A, Hao D, et al. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Futur Oncol. 2018;14:2861–2874.
   PubMed Web of Science ®Google Scholar
• Chung F-T, Ho M-Y, Fang Y-F, et al. The impact of sequence of chemotherapy and EGFR-TKI treatment on different EGFR mutation lung adenocarcinoma. BioMed Res Int. 2015;2015:1–8.
   Web of Science ®Google Scholar
• Cardona AF, Arrieta O, Zapata MI, et al. Acquired resistance to erlotinib in EGFR mutation-positive lung adenocarcinoma among hispanics (CLICaP). Target Oncol. 2017;12:513–523.
   PubMed Web of Science ®Google Scholar
• Rohatgi A. WebPlotDigitizer: HTML5 based online tool to extract numerical data from plot images. Version 4.2 [Internet]. San Francisco (CA); 2018. Available from: https://automeris.io/WebPlotDigitizer
   Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
   PubMed Web of Science ®Google Scholar
• Fonseca-Centeno Z, Heredia-Vargas AP, Ocampo-Téllez R, et al. Encuesta Nacional de la Situación Nutricional en Colombia 2010-ENSIN. Bogotá (DC): Instituto Colombiano de Bienestar Familiar; 2011.
   Google Scholar
• Wu Y-L, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017;104:119–125.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–640.
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236–1244.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): survival follow-up results of JO25567. J Clin Oncol. 2018;36:9007.
   Web of Science ®Google Scholar
• Furuya N, Fukuhara T, Saito H, et al. Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. J Clin Oncol. 2018;36:9006.
   Web of Science ®Google Scholar
• Zappa F, Droege C, Betticher D, et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung Cancer. 2012;78:239–244.
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.
   PubMed Web of Science ®Google Scholar
• Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos - CNPMDM. Circular 03 de 2017: por la cual se incorporan unos medicamentos al régimen de control directo con fundamento en la metodología de la Circular 03 de 2013 de la CNPMDM, se fija su precio máximo de venta y se dictan otras disposiciones [Internet]. 2017. [cited 2019 Mar 19]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/circular-03-2017.pdf.
   Google Scholar
• Chouaid C, Luciani L, LeLay K, et al. Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non-small cell lung cancers. J Thorac Oncol. 2017;12:1496–1502.
   PubMed Web of Science ®Google Scholar
• Gu X, Zhang Q, Chu Y-B, et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 2019;127:84–89.
   PubMed Web of Science ®Google Scholar
• Kimura M, Yasue F, Usami E, et al. Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Mol Clin Oncol. 2018. DOI:10.3892/mco.2018.1640
   Web of Science ®Google Scholar
• Aguiar PN, Haaland B, Park W, et al. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. JAMA Oncol. 2018;4:1080–1084.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q, et al. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019;24:349–357.
   PubMed Web of Science ®Google Scholar
• Cai H, Zhang L, Li N, et al. Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small cell lung cancer in China. Clin Ther. 2019;41:280–290.
   PubMed Web of Science ®Google Scholar